| European Case Law Identifier: | ECLI:EP:BA:2009:T060105.20091202 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 02 December 2009 | ||||||||
| Case number: | T 0601/05 | ||||||||
| Application number: | 94102560.3 | ||||||||
| IPC class: | C12P 21/08 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Anti-TNF alpha human monoclonal antibodies | ||||||||
| Applicant name: | Bayer Corporation | ||||||||
| Opponent name: | Centocor, Inc. Abbott Laboratories |
||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: | |||||||||
| Keywords: | Admission of late-filed documents - (partly) Admission of late-filed auxiliary requests 1 to 3 - (no) Main request - sufficiency of disclosure - (no) Auxiliary request 4 - added matter, extension of scope (no); clarity and support (yes); sufficiency of disclosure, novelty, inventive step (yes) Right to be heard violated by (i) non-admission of parts of documents and (ii) limitation of time to speak at oral proceedings (no) |
||||||||
| Catchwords: |
see points 11 to 17, 21 to 44 and 121 to 126 |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t050601eu3.html
Date retrieved: 17 May 2021